Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Palandri

Showing results (51-60 of 187) with videos related to

Pageof 19
Sort By:
The Lancet. Haematology|May 21, 2022
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b studyFrancesco Passamonti, Francesca Palandri, Guray Saydam, et al.
Oncoimmunology|September 14, 2020
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosisMartina Barone, Lucia Catani, Francesca Ricci, et al.
Mediators of Inflammation|August 18, 2018
Mobilized Peripheral Blood versus Cord Blood: Insight into the Distinct Role of Proinflammatory Cytokines on Survival, Clonogenic Ability, and Migration of CD34<sup>+</sup> CellsDorian Forte, Daria Sollazzo, Martina Barone, et al.
British Journal of Haematology|October 4, 2024
The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real-world study on AIFA monitoring registriesMassimo Breccia, Simone Celant, Francesca Palandri, et al.
Oncotarget|June 16, 2016
Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro studyDaria Sollazzo, Dorian Forte, Nicola Polverelli, et al.
Future Oncology (London, England)|June 6, 2025
Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosisLucia Masarova, Srdan Verstovsek, Francesca Palandri, et al.
Oncoimmunology|November 11, 2017
Mutations in <i>JAK2</i> and <i>Calreticulin</i> genes are associated with specific alterations of the immune system in myelofibrosisMarco Romano, Daria Sollazzo, Sara Trabanelli, et al.
Oncotarget|April 20, 2017
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric studyMargherita Perricone, Nicola Polverelli, Giovanni Martinelli, et al.
Annals of Hematology|February 24, 2022
Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectivesNicola Vianelli, Giuseppe Auteri, Francesco Buccisano, et al.
The Lancet. Oncology|December 6, 2016
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b studyFrancesco Passamonti, Martin Griesshammer, Francesca Palandri, et al.
Pageof 19

Showing results (51-60 of 187) with videos related to

Sort By:
Pageof 19
The Lancet. Haematology|May 21, 2022
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b studyFrancesco Passamonti, Francesca Palandri, Guray Saydam, et al.
Oncoimmunology|September 14, 2020
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosisMartina Barone, Lucia Catani, Francesca Ricci, et al.
Mediators of Inflammation|August 18, 2018
Mobilized Peripheral Blood versus Cord Blood: Insight into the Distinct Role of Proinflammatory Cytokines on Survival, Clonogenic Ability, and Migration of CD34<sup>+</sup> CellsDorian Forte, Daria Sollazzo, Martina Barone, et al.
British Journal of Haematology|October 4, 2024
The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real-world study on AIFA monitoring registriesMassimo Breccia, Simone Celant, Francesca Palandri, et al.
Oncotarget|June 16, 2016
Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro studyDaria Sollazzo, Dorian Forte, Nicola Polverelli, et al.
Future Oncology (London, England)|June 6, 2025
Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosisLucia Masarova, Srdan Verstovsek, Francesca Palandri, et al.
Oncoimmunology|November 11, 2017
Mutations in <i>JAK2</i> and <i>Calreticulin</i> genes are associated with specific alterations of the immune system in myelofibrosisMarco Romano, Daria Sollazzo, Sara Trabanelli, et al.
Oncotarget|April 20, 2017
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric studyMargherita Perricone, Nicola Polverelli, Giovanni Martinelli, et al.
Annals of Hematology|February 24, 2022
Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectivesNicola Vianelli, Giuseppe Auteri, Francesco Buccisano, et al.
The Lancet. Oncology|December 6, 2016
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b studyFrancesco Passamonti, Martin Griesshammer, Francesca Palandri, et al.
Pageof 19